pfizer

Celgene's second quarter results beat estimates and the company lifted 2018 outlook. Celgene will not be increasing the price of its products this year. https://news.alphastreet.com/celgene-q2-2018-earnings/

Investors have welcomed the move of Eli Lilly's decision to separate Elanco Animal Health business. Lilly stock hits a new 52-week high after the earnings announcement. David Ricks said, "As the responses to the Blueprint are considered, we are hopeful that progress will be made on implementing...

The latest pharma giant to bow to Trump’s pressure on drug price is Merck (MRK). The company announced on Thursday that it would lower price on at least six of its drug in the US by 10% or more. https://news.alphastreet.com/merck-joins-pharma-giants-in-lowering-drug-prices/

Trump has been speaking and tweeting about the higher drug prices for nearly two years and still he has not taken any steps in reducing the prices of the drugs. Pfizer and other pharma companies are taking advantage and increasing their drug prices often. When will this stop...

Pfizer blockbuster drug Xeljanz has won itself a new regulatory approval to treat adults with inflammatory bowel disease (IBD). This recent approval will help propel the company’s sales significantly. Pfizer’s Xeljanz is the first and only JAK inhibitor that obtained the FDA’s blessing to treat...

I am moving through the interview process for PHR 1 and am excited. The only thing I have reservations around are vacation days and the likelihood of layoffs. I come from a company with a generous 23days off per year with option to buy another week and 8 company holidays. I see at Pfizer it...

Pfizer posted a 1% improvement in revenues of $12.9 billion for the first quarter of 2018. Reported net income jumped 14% to $3.5 billion, while adjusted net income grew 11% to $4.6 billion. Reported EPS rose 15% to $0.59, while adjusted EPS grew 12% to $0.77 compared to last year. While revenue...

After weeks of offers and speculations, a deal has finally been struck in the consumer health space, though not really in an expected manner. P&G has ditched Pfizer’s consumer health unit to buy the same business of rival Merck, which was eyed by Mylan NV. P&G was willing to pay $15 billion for...

Both Pfizer and Merck planned to dispose their consumer health businesses since they failed to return profits, dampening their efforts to innovate in other segments. However, bidders eventually lost interest in Merck’s consumer health line, even as the auction of Pfizer’s consumer health unit...

P&G eyes Pfizer’s consumer business https://news.alphastreet.com/pg-eyes-pfizers-consumer-business/

All good things come to an end — and that includes Pfizer’s run with its blockbuster drug Viagra. The drugmaker’s little blue pill did help many deal with erectile dysfunctions (and then some more!) while generating billions for the company in its two decades. With no more exclusive rights to...

Pfizer (PFE) has been contemplating on selling its consumer healthcare division for some time, and it had found two bidders - British pharmaceutical giants GlaxoSmithKline and Reckitt Benckiser. However, with Reckitt announcing its decision to back out of the race yesterday to pursue its $16.6...

When providing the outlook for 2018, Saunders said that Allergan faces LOE losses in 2018. But still it has got good long-term prospects. Saunders says that current stock price doesn't reflect Allergan's true value. Wall Street gives thumbs up to his speech.

http://alph.st/bf3c0558 Lilly joins the migraine drug race with Novartis and Amgen, as FDA accepts to review Lilly's Galcanezumab. Already, Teva filed a lawsuit in October 2017, seeking to block Lilly's migraine drug to market in the U.S. The size of the migraine market is expected to more than...

Allergan swings to quarterly loss on charges related to Restasis and Teva holding. Given the Federal Court's decision, plans to mitigate the financial impact of generic competition http://alph.st/b68181eb

InnoPharma, a subsidiary of Pfizer and Allergan reaches a settlement on Restasis patent. Out of the four contestants, Mylan, Teva and Akorn are still contesting the patents in the federal court. http://alph.st/b3437240

Allergan reaches a settlement with InnoPharma, a subsidiary of Pfizer on Restasis patent. Out of the four contestants, Mylan, Teva and Akorn are still contesting the patents in the federal court. http://alph.st/b3437240

President Donald Trump announced that pharma giants Pfizer and Merck are collaborating with Gorilla Glass manufacturer Corning for manufacturing a new glass (Valor Glass), which is superior and reliable for the delivery of injectable drugs. Corning is planning to invest $500MM creating 1,000...

President Trump announced that pharma giants Merck and Pfizer are collaborating with Gorilla Glass manufacturer Corning for manufacturing a new glass (Valor Glass), which is superior and reliable for the delivery of injectable drugs. Corning is planning to invest $500MM creating 1,000 jobs...

Which Pfizer products are manufactured at or planned for the Kansas plant?